| Study |
|
Exclusion reasons |
Remarks |
Reference(s) |
|
|
Gilboa, 2021
|
-
|
|
|
Gilboa M J Infect Dis 2021 Nov 29;jiab584. 10.1093/infdis/jiab584
|
|
|
UKHSA report 33 (23 december 2021), 2021
|
case control
|
|
no usable date (only presented graphically without possibility to estimate values of CI limits)
|
|
|
|
Musser, 2021
|
retrospective cohort
|
|
|
Musser JM et al. medrxiv;2021.07.19.21260808v1 10.1101/2021.07.19.21260808
|
|
|
UKHSA 31 december 2021, 2021
|
case control
|
|
duplicate with Andrews 2021
|
|
|
|
Rosenberg, 2021
|
retrospective cohort
|
|
No Confidence Interval reported, not usable in meta-analysis
|
Rosenberg ES et al. MMWR Morb Mortal Wkly Rep 10.15585/mmwr.mm7034e1
|
|
|
Scobie, 2021
|
case control
|
|
|
Scobie HM et al. MMWR Morb Mortal Wkly Rep 10.15585/mmwr.mm7037e1
|
|
|
Southern California (Lewnard), 2022
|
retrospective cohort
|
|
hospitalization rate among cases testing positive for SARS-CoV-2 infection : not a directly estimation of vaccine efficacy
|
Lewnard JA et al. medrxiv;2022.01.11.22269045v1 10.1101/2022.01.11.22269045
|
|
|
PHE variants (Technical briefing 12 22 may 2021), 2021
|
case control
|
|
duplicate
|
|
|
|
PHE (Stowe), 2021
|
retrospective cohort
|
|
duplicate
|
|
|
|
Candidate COVID-19 Vaccine (COV001), 2020
|
randomized controlled trial
|
|
|
Folegatti PM Lancet 2020 Aug 15;396(10249):467-478. 10.1016/S0140-6736(20)31604-4
|
|
|
PHE Technical briefing 16 (11/18 June 2021), 2021
|
retrospective cohort
|
|
duplicte
|
|
|
|
Babamahmoodi, 2021
|
observational study
|
no control group
|
|
Babamahmoodi F et al. researchsquare 10.21203/rs.3.rs-709499/v1
|
|
|
Montgomery, 2021
|
retrospective cohort
|
no control group
|
|
Montgomery J et al. JAMA Cardiol 10.1001/jamacardio.2021.2833
|
|
|
Barrett, 2020
|
-
|
no control group
|
phase 1/2
|
Barrett JR et al. Nat Med 10.1038/s41591-020-01179-4
|
|
|
Kawasuji, 2022
|
-
|
no control group
|
|
Kawasuji H et al. medrxiv;2022.02.23.22271433v1 10.1101/2022.02.23.22271433
|
|
|
Falsey, 0
|
-
|
no control group
|
|
Falsey AR et al. New England Journal of Medicine 10.1056/NEJMc2113468
|
|
|
NCT04276896, 0
|
single-arm
|
no control group
|
|
|
|
|
Ruddy, 2021
|
case series
|
no control group
|
|
Ruddy JA AIDS 2021 Sep 1;35(11):1872-1874. 10.1097/QAD.0000000000002945
|
|
|
study 101 dose finding, 2020
|
non randomized controlled trial
|
no control group
|
phase 1
|
Anderson EJ N Engl J Med 2020 Sep 29. 10.1056/NEJMoa2028436 Jackson LA N Engl J Med 2020 Nov 12;383(20):1920-1931. 10.1056/NEJMoa2022483
|
|
|
Tobaiqy M, 2021
|
case series
|
no control group
|
retrospective descriptive study using spontaneous reports submitted to the EV database in the period from 17 February to 12 March 2021
|
Tobaiqy M Vaccines (Basel) 2021 Apr 16;9(4):393. 10.3390/vaccines9040393
|
|
|
Danza, 2022
|
case series
|
no control group
|
Omicron became the predominant SARS-CoV-2 variant in LAC during the week ending December 18, accounting for 57% of all sequenced specimens;Omicron prevalence continued to increase, accounting for 99% of all sequenced specimens for the week ending January 8, 2022
|
Danza P et al. MMWR Morb Mortal Wkly Rep 10.15585/mmwr.mm7105e1
|
|
|
BioNTech phase 2 (Walsh), 2020
|
randomized controlled trial
|
no clinically relevant endpoint
|
phase 1-2 ; dose-escalation : 13 groups of 15 participants
|
|
|
|
Nanthapisal, 2022
|
randomized controlled trial
|
no clinically relevant endpoint
|
To evaluate immunogenicity and reactogenicity of standard- versus low-doseChAdOx1 nCoV-19 vaccine booster after CoronaVac in healthy adults
|
Nanthapisal S et al. medrxiv;2022.02.15.22270974v1 10.1101/2022.02.15.22270974
|
|
|
Liu, 2021
|
randomized controlled trial
|
no clinically relevant endpoint
|
|
Liu J J Infect Dis 2021 Dec 27;jiab627. 10.1093/infdis/jiab627
|
|
|
COV-BOOST, 2021
|
randomized controlled trial
|
no clinically relevant endpoint
|
Phase 2 trial.
|
Munro APS Lancet 2021 Dec 2;S0140-6736(21)02717-3. 10.1016/S0140-6736(21)02717-3
|
|
|
UKHSA (report W4- 27 January), 2022
|
retrospective cohort (claims database)
|
other
|
study replaces by next report (Kiresbom et al)
|
Uk Health Security agency
|
|
|
Moderna preclinical (Corbett), 2020
|
randomized controlled trial
|
other
|
|
Corbett KS N Engl J Med 2020 Oct 15;383(16):1544-1555. 10.1056/NEJMoa2024671
|
|
|
Pfizer 16-25 years phase 3, 0
|
randomized controlled trial
|
other
|
very preliminary results from a press release
|
|
|
|
Ou, 2021
|
case series
|
other
|
safety and reactogenicity, no immunogenicity
|
Ou MT Transplantation 2021 Apr 9. 10.1097/TP.0000000000003780
|
|
|
Chen, 2021
|
randomized controlled trial
|
other
|
|
Chen J Zhonghua Liu Xing Bing Xue Za Zhi 2021 Dec 10;42(12):2077-2081. 10.3760/cma.j.cn112338-20210807-00617
|
|
|
Mattiuzzi, 2022
|
-
|
other
|
same population alder study than mattiuzzi, 2022
|
Mattiuzzi C Eur Geriatr Med 2022 Jan 24. 10.1007/s41999-022-00615-7
|
|
